Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma
Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma
Rituximab versus idelalisib in refractory CLL
New agents extend progression-free survival in double refractory myeloma
Aspirin analogues developed for anti-cancer effects on leukaemia
Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients